Aspartame
Aspartame is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| discount drug mart eye drops advanced relief | OTC monograph final | 2023-03-20 |
| equalactin laxative | C200263 | 2023-12-18 |
| equaline | OTC monograph not final | 2019-02-15 |
| equaline 12 hour decongestant | ANDA | 2023-08-03 |
| equaline acetaminophen | OTC monograph not final | 2023-08-08 |
| equaline adult tussin | OTC monograph final | 2023-08-21 |
| equaline advanced relief eye drops | C200263 | 2023-12-20 |
| equaline all day allergy | ANDA | 2023-08-02 |
| equaline allergy | C200263 | 2024-07-19 |
| equaline allergy relief | ANDA | 2023-07-24 |
Show 87 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonoscopy | D003113 | — | — | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
| Pyruvate dehydrogenase complex deficiency disease | D015325 | EFO_0007459 | E74.4 | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | 1 | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | 1 | — | — | 1 |
| Child nutrition disorders | D015362 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | 3 | 5 |
| Xerostomia | D014987 | — | K11.7 | 1 | 1 | — | — | 2 | 3 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | 1 | — | — | 1 | 2 |
| Ototoxicity | D000081015 | — | — | — | 1 | — | — | — | 1 |
| Mucositis | D052016 | EFO_1001898 | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | 1 | — | — | — | — | 1 |
| Escherichia coli infections | D004927 | EFO_1001318 | B96.20 | 1 | — | — | — | — | 1 |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Dental plaque | D003773 | — | — | 1 | — | — | — | — | 1 |
| Hydrogen-ion concentration | D006863 | — | — | 1 | — | — | — | — | 1 |
| Salivation | D012472 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 13 | 13 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 7 | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 6 | 6 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 5 | 5 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 5 | 5 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 5 | 5 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 5 | 5 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 4 | 4 |
| Weight loss | D015431 | HP_0001824 | — | — | — | — | — | 3 | 3 |
| Feeding behavior | D005247 | — | — | — | — | — | — | 3 | 3 |
Show 56 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aspartame |
| INN | aspartame |
| Description | Aspartame is a dipeptide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of methyl L-phenylalaninate. Commonly used as an artificial sweetener. It has a role as a sweetening agent, a nutraceutical, a micronutrient, a xenobiotic, an environmental contaminant, an apoptosis inhibitor and an EC 3.1.3.1 (alkaline phosphatase) inhibitor. It is a dipeptide, a carboxylic acid and a methyl ester. It is functionally related to a L-aspartic acid and a methyl L-phenylalaninate. It is a tautomer of an aspartame zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 22839-47-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL171679 |
| ChEBI ID | 2877 |
| PubChem CID | 134601 |
| DrugBank | DB00168 |
| UNII ID | Z0H242BBR1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,153 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,365 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use